Sirion enters market with eye pain drug for surgery

TAMPA, Fla. A drug for treating pain and inflammation associated with ocular surgery has become available, the drug’s manufacturer announced Monday.

Sirion Therapeutics announced the availability of Durezol (difluprednate ophthalmic emulsion), in 0.05 percent concentrations.

“We are excited to provide eye care professionals with a new and powerful topical steroid,” Sirion senior vice president of sales and marketing Susan Benton said. “Because Durezol is the first and only steroid with an approval for both inflammation and pain, it is the first innovation in the strong steroid class in over 35 years.”

Sirion specializes in biologic ophthalmic treatments.